Ashutosh Kumar Maurya

Mr. Ashutosh Kumar Maurya


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Cells
Verified
Journal Article
Open access
PDF file
GRGRACE RAJI
GRACE RAJI
APAswini Poyyakkara
Aswini Poyyakkara
AKAnjali Kunhi Krishnan
Anjali Kunhi Krishnan
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
UCUdeshna Changmai
Udeshna Changmai
SKSAMEER KUMAR
SAMEER KUMAR
Acquisition of resistance to cisplatin is a major impediment to the success of cisplatin-based combination therapies for cancer. Recent studies indicate that exosomal miRNAs derived from drug-resistant tumour cells can confer resistance properties to recipient cells by a horizontal transfer mechanism. Although the role of horizontal transfer of a few miRNAs has been described, little is known about the concerted action of horizontal transfer of miRNAs in conferring cisplatin resistance. The present study was designed to identify the role of miR-643, which is one of the most significantly increased miRNA in exosomes released from cisplatin-resistant Heptocarcinoma cells, in altering the cisplatin resistance properties of recipient cells. Drug-sensitivity assays involving miR-643 revealed that ectopic expression of miR-643 can desensitise the cells towards cisplatin. Furthermore, we identified APOL6 as a major target of miR-643. Further mechanistic studies showed that miR-643 can modulate APOL6 mRNA and protein levels, leading to a reversal of APOL6-mediated apoptosis. Altogether, our results suggest an APOL6-dependent mechanism for miR-643 mediated cisplatin resistance upon the horizontal transfer across cell types.

21 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
AMAshish Kumar Maurya
Ashish Kumar Maurya
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
Exosomal microRNAs (miRNAs) have emerged as promising candidates for cancer biomarker discovery due to their unique properties as stable, non-invasive, and informative molecules in body fluids. These small, membrane-bound vesicles play critical roles in intercellular communication by transferring miRNAs, which regulate gene expression and influence various biological processes, including cancer progression, metastasis, and drug resistance. Recent advancements in exosome isolation and miRNA profiling technologies have unveiled their potential for early cancer detection, prognosis, and therapeutic monitoring. Exosomal miRNAs offer several advantages over traditional biomarkers, including ease of detection in liquid biopsies (e.g., blood, urine), the ability to reflect the molecular landscape of tumors, and their association with both primary and metastatic cancer sites. However, despite the growing body of evidence supporting their utility, challenges such as standardization of isolation methods, variability in miRNA expression across cancer types, and the need for large-scale clinical validation remain significant barriers to clinical translation. This review highlights the biological mechanisms by which exosomal miRNAs influence cancer biology, their clinical applications in cancer diagnosis and therapy, and the technological advancements driving their profiling. Additionally, we discuss the current challenges and future directions for harnessing exosomal miRNAs in precision oncology.

4 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAshutosh Maurya
Ashutosh Maurya
SRSweta Saswati Rath
Sweta Saswati Rath
AMAshish Kumar Maurya
Ashish Kumar Maurya
SVSameer Kumar V.B
Sameer Kumar V.B
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
RPRajendra Pilankatta
Rajendra Pilankatta
Cancer remains one of the leading causes of death worldwide, demanding continuous innovation in therapeutic strategies. Traditional chemotherapeutic agents, though effective in certain contexts, are limited by systemic toxicity, drug resistance, and non-specific targeting. Over the past two decades, the landscape of anticancer drug discovery has undergone a paradigm shift with the emergence of molecularly targeted agents, immunotherapies, and rational drug design technologies. Advancements in genomics, proteomics, and structural biology have enabled the identification of novel cancer-specific targets, while computational and artificial intelligence (AI)-driven approaches are accelerating lead optimization and predictive modeling of drug efficacy and toxicity. The development of antibody–drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders (PROTACs) represents a new generation of therapies capable of addressing previously “undruggable” targets. Meanwhile, patient-derived organoids, 3D co-culture systems, and high-content screening platforms are refining preclinical evaluation and improving translational success rates. This review summarizes the recent trends in anticancer drug discovery, highlights the integration of computational and experimental pipelines, and explores emerging modalities poised to redefine cancer treatment in the coming decade. The future of anticancer drug discovery lies in combining precision oncology, AI-based design, and systems-level modeling to deliver safer, more effective, and personalized therapies against cancer’s molecular complexity.

4 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
SASr Aiswarjinee
Sr Aiswarjinee
AMAshish Kumar Maurya
Ashish Kumar Maurya
SVSameer Kumar V.B
Sameer Kumar V.B
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
RPRajendra Pilankatta
Rajendra Pilankatta
Cancer remains one of the foremost challenges in global health, distinguished by profound biological complexity, heterogeneity, and therapeutic resistance. Over recent decades, oncology has transitioned from broadly cytotoxic regimens toward molecularly targeted and immune-based therapies; nevertheless, substantial clinical gaps persist. The emergence of artificial intelligence (AI) represents a transformative advance in this continuum, offering unprecedented capacity to integrate and interpret multidimensional biomedical data. AI-driven methodologies now play pivotal roles in early cancer detection, histopathological and radiomic assessment, biomarker discovery, and the prediction of therapeutic response. Furthermore, AI is accelerating drug discovery and enabling adaptive, patient-specific treatment strategies that transcend conventional evidence-based paradigms. This review synthesizes recent progress at the interface of AI and oncology, highlighting how machine learning, deep learning, and computational modeling are reshaping diagnostic precision, therapeutic optimization, and clinical decision-making. We also examine persisting challenges, including data heterogeneity, algorithmic transparency, and ethical implementation in real-world settings. Integrating computational intelligence with precision medicine heralds a future of cancer care that is predictive, preventive, and personalized—where human expertise and AI converge to redefine the boundaries of cancer treatment.

7 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
SASr Aiswarjinee
Sr Aiswarjinee
AMAshish Kumar Maurya
Ashish Kumar Maurya
VKV.B. Sameer Kumar
V.B. Sameer Kumar
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
RPRajendra Pilankatta
Rajendra Pilankatta
Complexity, heterogeneity, and therapeutic resistance continue to make cancer one of the most challenging diseases to diagnose and treat. Despite substantial advances in molecular biology and immuno-oncology, persistent limitations in early detection, targeted delivery, and therapeutic precision continue to impede effective management. Over the past two decades, nanotechnology has emerged as a transformative frontier, offering innovative strategies for cancer diagnostics and treatment. Engineered nanomaterials—encompassing liposomes, polymeric nanoparticles, quantum dots, and metallic nanostructures—enable precise tumor targeting, enhanced imaging resolution, and controlled therapeutic release.In diagnostics, nanoscale biosensors and imaging probes have markedly improved the sensitivity and specificity of biomarker detection and visualization. In therapeutics, nanocarriers have demonstrated the capacity to minimize systemic toxicity and optimize pharmacokinetics, thereby improving clinical efficacy. Recent developments, including smart and stimuli-responsive nanoplatforms, nanorobotics, and integrated theranostic systems, are redefining the landscape of personalized cancer care. Nonetheless, critical translational challenges remain, particularly regarding large-scale manufacturing, long-term biosafety, and regulatory validation.This review critically examines the evolution of nanotechnology in oncology, synthesizing advances in nanodiagnostics and nanotherapeutics, assessing current clinical progress, and outlining future directions toward achieving precision nanomedicine in cancer diagnosis and therapy.

7 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
SASr Aiswarjinee
Sr Aiswarjinee
AMAshish Kumar Maurya
Ashish Kumar Maurya
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
AMAshutosh Kumar Maurya
Ashutosh Kumar Maurya
RPRajendra Pilankatta
Rajendra Pilankatta
Human cytomegalovirus (HCMV) has emerged as a potential oncomodulatory agent implicated in the pathogenesis of several cancers, although its precise role in tumorigenesis remains a subject of debate. This review synthesizes five decades of research examining the involvement of HCMV in cancer, with particular focus on molecular mechanisms by which the virus may contribute to tumor progression, including immune evasion, chronic inflammation, and modulation of cell cycle and signaling pathways. Evidence of HCMV detection in malignancies such as glioblastoma, breast, colorectal, and prostate cancers is critically reviewed, alongside ongoing controversies regarding its causal versus passenger role in oncogenesis.The review further explores current and emerging antiviral and immunotherapeutic strategies targeting HCMV within oncological settings, highlighting their potential translational relevance and associated challenges. By reassessing oncogenic hypotheses and therapeutic opportunities, this article aims to provide a comprehensive perspective on the complex interplay between HCMV and cancer biology, and to evaluate its potential as a novel target for cancer prevention and therapy.